Literature DB >> 29363748

Haematology patients and the risk of transfusion transmitted infection.

Louise I Ainley1, Patricia E Hewitt2.   

Abstract

A 2014 study by NHS Blood and Transplant indicated that over one quarter of red cells were transfused to patients with haematological conditions. For platelet components, the figure is higher. Certain diagnostic groups, such as haemoglobinopathies, myelodysplastic syndromes and some haemato-oncology patients, receive multiple transfusion episodes, either over long periods, or more intensively over shorter periods. Haematology patients account for the majority of the multi-transfused population. The risk of transfusion-transmitted infection (TTI) increases with number of donor exposures, and the consequences of TTI are often more significant in immunosuppressed individuals. Historically, use of pooled plasma products in patients with clotting disorders resulted in widespread transmission of hepatitis B virus, hepatitis C virus and human immunodeficiency virus before effective screening and viral inactivation methods were introduced.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  blood components; emerging infections; transfusion-transmitted infection

Mesh:

Year:  2018        PMID: 29363748     DOI: 10.1111/bjh.15030

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Significance of Adopting Nucleic Acid Amplification Technique for Blood Donor Screening in a Resource Limited Setting: A Study from a Single Centre in South India.

Authors:  Sudha Ranganathan; Ranganathan N Iyer; Nagalla Balakrishna
Journal:  Indian J Hematol Blood Transfus       Date:  2021-10-27       Impact factor: 0.915

2.  Budget impact of implementing platelet pathogen reduction into the Italian blood transfusion system.

Authors:  Americo Cicchetti; Silvia Coretti; Francesco Sacco; Paolo Rebulla; Alessandra Fiore; Filippo Rumi; Rossella Di Bidino; Luz I Urbina; Pietro Refolo; Dario Sacchini; Antonio G Spagnolo; Emanuela Midolo; Giuseppe Marano; Blandina Farina; Ilaria Pati; Eva Veropalumbo; Simonetta Pupella; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2018-09-03       Impact factor: 3.443

3.  Hepatitis B virus infection among oncohematologic disease patients in Central Brazil: prevalence, risk factors and immunization.

Authors:  Grécia C Pessoni; Tássia A Marinho; Megmar M Santos Carneiro; Regina M Martins; Caroline C Soares; Leandro N Silva; Marcia A Matos; Adriano M Arantes; Juliana A Teles; Nathalia C Santos; Sheila Araujo Teles
Journal:  Hematol Transfus Cell Ther       Date:  2019-03-28

4.  Deep sequencing applied to the analysis of viromes in patients with beta-thalassemia.

Authors:  Ian Nunes Valença; Rafael Bezerra Dos Santos; Kamila Chagas Peronni; Virginie Sauvage; Mathias Vandenbogaert; Valérie Caro; Wilson Araújo da Silva Junior; Dimas Tadeu Covas; Ana Cristina Silva-Pinto; Syria Laperche; Simone Kashima; Svetoslav Nanev Slavov
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2021-05-24       Impact factor: 1.846

5.  Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry.

Authors:  Eric Rondeau; Spero R Cataland; Imad Al-Dakkak; Benjamin Miller; Nicholas J A Webb; Daniel Landau
Journal:  Kidney Int Rep       Date:  2019-08-02

6.  Energy Requirements for Loss of Viral Infectivity.

Authors:  Caroline E R Rowell; Hana M Dobrovolny
Journal:  Food Environ Virol       Date:  2020-08-05       Impact factor: 2.778

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.